Zymo Research Corporation, The Epigenetics Company, announces the launch of their services for genetic, epigenetic, and expression analysis. Zymo Research has developed products and technologies for epigenetics research for over a decade, and two years ago introduced unique methods for genome-wide analysis of DNA methylation. Since then, Zymo Research has continued to expand their epigenetic analysis capabilities and is now the most established and complete provider of epigenetic services. Services are available for investigating DNA methylation (5-mC) and hydroxymethylation (5-hmC), as well as targeted DNA methylation analysis of single or multiple genetic loci. Multiple service options are available to the researcher; each offering varying degrees of genome coverage, so customers can choose the analysis best suited for their needs. Zymo Research’s epigenetic services make genome-wide analyses affordable for nearly every budget. No experience with sequencing or bioinformatics technologies is required – simply submit the samples and receive high quality, easy-to-interpret publication-ready data and figures.
There are many unique benefits to using the services offered by Zymo Research, including: the most highly-cited chemistries for bisulfite treatment of DNA for 5-mC analysis, novel library prep workflows for ultra-low DNA inputs, and custom-designed bioinformatics pipelines to ensure seamless data handling, analysis, and delivery. Additionally, the scientists at Zymo Research have recently developed a novel technique to determine DNA hydroxymethylation levels on a genome-wide scale called Reduced Representation Hydroxymethylation Profiling (RRHP). RRHP, a service offered exclusively by Zymo Research, is the only method available for reliable single base-pair resolution and strand-specific profiling of 5-hmC modifications in DNA. Additional services are also available for genetic, epigenetic, and expression analysis, including 5-hmC CapSeq, ChIP-Seq, nucleosome position mapping, RNA-Seq, targeted DNA sequencing, large and small genome sequencing, mitochondrial DNA sequencing, and analysis of DNA modifications by mass spectrometry. These services can be combined and customized to meet the needs of the researcher depending on the requirements of any particular study.
According to Dr. Marc Van Eden, V.P. of Business Development at Zymo Research, “High throughput Next-Gen sequencing is no longer only reserved for those labs with seemingly unlimited resources. Now, with the service platforms and bioinformatics technologies from Zymo Research, every laboratory will have access to genome-wide genetic and epigenetic analysis. This will mark the beginning of a new era in epi-biomarker discovery and validation that will aid in the diagnostics and prognostics of human diseases, and facilitate personalized medicine and companion diagnostics to optimize the efficiency of individualized drug treatment. Also, we may begin to ask how things like the environment and our diet affect who we are and who we will likely become.” Dr. Van Eden continues, “The bioinformatics experts at Zymo Research take care of the number crunching and bioinformatics analysis so the customer doesn’t have to. In addition to sending customers raw data, we also send results in easy-to-digest customizable reports. Now genome-wide analysis and bioinformatics couldn’t be easier.”